Targeting a cure

Our mission is to process and harmonize Alzheimer’s Disease genetic and genomic data to facilitate and expedite gene discovery and drug target identification.

Raw Data AnalysisReadyData Data Processing VariantAnnotation QualityControl

From raw to analysis-ready data

Whole-genome and whole-exome sequencing data are processed into CRAMs, gVCFs and then joint called into project level VCFs.

Collaborating with researchers around the world

GCAD is facilitating collaborations between cohorts and researchers studying neurodegenerative diseases from all over the world.

Latest News

  • ADSP releases quality-controlled whole-genome data on nearly 17,000 samples

    NIAGADS is pleased to announce the release of the Release 3 (R3) WGS ADSP quality-controlled joint genotype called pVCF containing 16,905 samples. Additionally, this release includes a quality-controlled X-chromosome pseudoautosomal region (PAR) pVCF containing 20,503 whole exomes from Release 2 (R2) as well as R3 individual-level VCF structural variant (SV)…

  • ADSP Functional Genomics Consortium Launch

    ADSP, the Alzheimer’s Disease Sequencing Project, has emerged as a powerful tool for genetics researchers in their work on genomics data analysis. This summer, NIA awarded six grants to fund projects that form the core of the ADSP Functional Genomics Consortium (FGC). This significant boost will support consortium researchers as they develop free and accessible tools, […]

  • Alzheimer’s Disease Variant Portal (ADVP): The Newest Curated Population-specific Alzheimer’s Disease Genetics Resource

    By Fernanda Ruiz, NOVA Research Company Alzheimer’s Disease (AD) is a devastating disease that affects more than 6 million Americans, a number that is projected to increase considerably in the near future. Scientists looking for the causes of AD use different approaches, including genomic studies like genome-wide association studies (GWAS), that detect associations between genetic […]